Entera Bio Ltd. Financing cash flow

Financing cash flow of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Financing cash flow growth rates and interactive chart.


Highlights and Quick Summary

  • Financing cash flow for the quarter ending June 29, 2020 was $-35 Thousand (a -104.23% decrease compared to previous quarter)
  • Year-over-year quarterly Financing cash flow decreased by -119.23%
  • Annual Financing cash flow for 2019 was $12.7 Million (a 31.46% increase from previous year)
  • Annual Financing cash flow for 2018 was $9.62 Million (a -13.35% decrease from previous year)
  • Twelve month Financing cash flow ending June 29, 2020 was $13.5 Million (a -0.24% decrease compared to previous quarter)
  • Twelve month trailing Financing cash flow increased by 8535.26% year-over-year
Trailing Financing cash flow for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$13.5 Million $13.5 Million $12.7 Million $156 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Financing cash flow of Entera Bio Ltd.

Most recent Financing cash flowof ENTX including historical data for past 10 years.

Interactive Chart of Financing cash flow of Entera Bio Ltd.

Entera Bio Ltd. Financing cash flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.04 $0.83
2019 $12.5 $0.18 $-0.0 $-0.02 $12.65
2018 $0.0 $9.62 $9.62
2017 $11.11 $11.11

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.